KDC-MN-237 – Kodiac biolabs

Plain-language summaryIntrigue 62 / 100

Brexpiprazole (Rexulti) is Otsuka’s refined successor to aripiprazole, approved in 2015. The key tuning is lower intrinsic activity at the dopamine D2 receptor (about 14 percent rather than aripiprazole’s 30 percent), which translates to less akathisia (motor restlessness), the side effect that drove many patients off aripiprazole. The receptor occupancy profile is otherwise broadly similar. Brexpiprazole has FDA approval for schizophrenia, as add-on to antidepressants for major depressive disorder, and notably became the first drug specifically approved for agitation associated with Alzheimer dementia in 2023. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Mature D2 partial agonist; a solid reference compound for intrinsic activity research, not a frontier target

Look, brexpiprazole is what happens when a well-understood mechanism gets refined rather than replaced. Otsuka took aripiprazole’s D2 partial agonist chassis and tuned the intrinsic activity down from about 30 percent to 14 percent. That’s real pharmacology. The result is reduced akathisia and a cleaner receptor profile, making it useful as a reference compound for separating out the consequences of D2 intrinsic activity from the other variables that shift across the atypical antipsychotic class. But from a research novelty standpoint, this conversation was largely over by the time Rexulti got FDA approval in 2015.

The mechanism profile is multi-target in the right ways: D2 partial agonism at Ki around 0.30 nM, 5-HT1A partial agonism at Ki around 0.12 nM, and 5-HT2A antagonism. Thats the third-generation antipsychotic formula that aripiprazole pioneered. Brexpiprazole doesn’t change the formula so much as optimize one parameter. For bench work probing the consequences of D2 intrinsic activity levels, it has genuine utility. Pair it with aripiprazole and cariprazine and you get a gradient of intrinsic activities to work across. That’s the legitimate research angle.

What’s actually interesting is the 2023 Alzheimer-associated agitation approval from the RAISE trial. In low-dopaminergic-tone patients, you want a partial agonist that doesn’t overshoot, and the low intrinsic activity specifically addresses that. The FDA approval validated the mechanism logic in a population where these distinctions really matter. We think that’s the most scientifically underappreciated part of the brexpiprazole story.

Evidence quality is solid. Multiple Phase 3 RCTs across schizophrenia, MDD adjunctive, and Alzheimer agitation give it a clinical database that most compounds in this library can’t claim. Translational signal is strong by antipsychotic standards. The problem is that a bench scientist looking for a novel target is going to find brexpiprazole thoroughly characterized. Pharmacokinetics are mapped (91-hour half-life, CYP3A4/2D6 metabolism). Receptor binding is quantified across labs. There’s not much terra incognita left.

Honestly, this is a compound that earns its library place as a reference tool and a case study in intrinsic activity pharmacology, not as a frontier target. We dont score it high because it isn’t asking a new question. It’s answering an old one very well. If your program needs a D2 partial agonist probe with low intrinsic activity and FDA-grade clinical data behind the mechanism, brexpiprazole is the right compound. If you’re hunting the frontier, look elsewhere.

Novelty: 22
Mechanism promise: 42
In-category differentiation: 35
Evidence quality: 75
Translational signal: 65
Research bench value: 38

Rationale Brexpiprazole is a 2015-approved incremental refinement of aripiprazole’s well-established D2 partial agonist mechanism, scoring low on novelty and differentiation but high on evidence quality and translational signal. Its primary research value is as a reference probe for intrinsic activity comparisons and, more recently, as a case study in how low D2 intrinsic activity performs in low-dopaminergic-tone populations following the 2023 Alzheimer agitation approval.

D2 partial agonist atypical antipsychotic

A second-generation D2 partial agonist refined from aripiprazole; lower D2 intrinsic activity producing reduced akathisia.

Abstract

Brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; CAS 913611-97-9; molecular formula C25H27N3O2S; molecular weight 433.57) is a D2 partial agonist developed at Otsuka as a successor to aripiprazole and approved by the FDA in 2015 under the trade name Rexulti. The structural change from aripiprazole replaces the 2,3-dichlorophenyl with a benzothiophen-4-yl, modulating receptor binding kinetics. D2 affinity (Ki approximately 0.30 nM) is comparable to aripiprazole, but intrinsic activity is lower (approximately 14 percent versus 30 percent), producing reduced akathisia and less D2 receptor activation in low-dopaminergic-tone regions. 5-HT1A partial agonism (Ki approximately 0.12 nM) and 5-HT2A antagonism are retained. Plasma half-life is 91 hours; metabolism is via CYP3A4 and CYP2D6. Approved for schizophrenia, MDD adjunctive, and (2023) Alzheimer-associated agitation. Used as the reference second-generation D2 partial agonist with reduced intrinsic activity.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-237Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-237

Brexpiprazole

Abstract

Read the full monograph